Innovent Biologics
Innovent Biologics, also known as Innovent, is a leading biopharmaceutical company headquartered in China (CN). Founded in 2011, the company has rapidly established itself in the biopharmaceutical industry, focusing on the development, manufacturing, and commercialisation of innovative therapies for oncology, autoimmune diseases, and other serious conditions.
With a strong presence in major operational regions across Asia and beyond, Innovent is recognised for its robust pipeline of monoclonal antibodies and biosimilars. Their flagship products, including the PD-1 inhibitor Tyvyt, have garnered significant attention for their unique mechanisms of action and efficacy.
Innovent's commitment to research and development has positioned it as a key player in the global market, achieving notable milestones such as successful partnerships and regulatory approvals that underscore its reputation for excellence in biopharmaceutical innovation.
-4 vs industry average
Innovent Biologics’s score of 34 is higher than 57% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Part of the Sustainability team at Innovent Biologics?
- Control how your company's emission story is told
- Respond to customers efficiently
- See who's viewing your profile
Industry Intensity
Pharmaceutical Preparation Manufacturing has below-average carbon intensity
Industry performance
The Pharmaceutical Preparation Manufacturing industry has reduced its overall emissions by 19% since 0
Emissions trajectory 2020 – 2028
Reported emissions
Scope 3 accounts for ••• of total emissions.
Innovent Biologics's reported carbon emissions
In 2025, Innovent Biologics reported total carbon emissions of approximately 101.9 million kg CO2e. This figure includes Scope 1 emissions of about 7.8 million kg CO2e, Scope 2 emissions of approximately 74.7 million kg CO2e, and Scope 3 emissions of around 19.5 million kg CO2e. The company has set a significant reduction target for its Scope 2 emissions, aiming for a 28% decrease in energy consumption per vial produced, reducing from 4,285 KWH/Kvials in 2024 to 3,096 KWH/Kvials in 2025. This initiative reflects Innovent's commitment to enhancing energy efficiency and reducing its carbon footprint. Innovent Biologics operates without cascading emissions data from a parent company, ensuring that its reported figures are independently sourced. The company continues to focus on sustainability and climate action as part of its operational strategy.
Unlock detailed emission data
Access structured emission data, company specific factors and auditable source documents
Innovent Biologics’s Climate Goals (2030 & 2050)
1 goal2025
28% reduction in Scope 2
Reduced by 28% (3,096 KWH/Kvials) in 2025 as compared with 2024 (4,285 KWH/Kvials)
2030
62% reduction in total GHG
Vs 2019 baseline. Validated by SBTi. Includes full supply chain.
2040
50% reduction in Scope 3 intensity
Across purchased goods and services and logistics.
See all 1 climate goals
Already have an account? Sign in now
Scope 3 top emissions categories
No scope 3 category breakdown has been disclosed yet.
Emissions comparison with industry peers
View similar organisations
Innovent Biologics
Usage policy
You’re welcome to quote or reference data from this page, but please include a visible link back to this URL. Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.
Where does DitchCarbondata come from?
Discover our data-driven methodology for measuring corporate climate action and benchmarking against industry peers
Learn moreCurious to see your top suppliers emissions?
Book a demo for a pilot project